Article Figures & Data
Figures
- FIGURE 1.
Serum clearance and biodistribution of 89Zr-Df-IAB22M2C. (A) Serum clearance of 89Zr-Df-IAB22M2C based on enzyme-linked immunosorbent assay measurements (limit of detection = 5 ng/mL). No minibody was detected in serum at the 0.2-mg dose. (B) Whole-body PET images of a patient at various times after injection of 89Zr-Df-IAB22M2C (1.5-mg minibody dose) demonstrating the distribution of 89Zr-Df-IAB22M2C in normal tissues and uptake in a nodal metastasis in the right neck (arrow), with good visualization of uptake in the nodal metastasis at 24–48 h after injection.
- FIGURE 2.
89Zr-Df-IAB22M2C uptake in normal tissues and tumor lesions versus time. (A) 89Zr-Df-IAB22M2C uptake in CD8-rich reference tissues in patients administered 0.5 and 1.5 mg of minibody mass. (B) 89Zr-Df-IAB22M2C uptake in CD8-poor reference tissues in patients administered 0.5 and 1.5 mg of minibody mass. (C) Box and whisker plots of 89Zr-Df-IAB22M2C uptake in tumor lesions from all subjects (n = 15). Boxes outline first and third quartile values. Median SUVMAX values are indicated by horizontal line and mean SUVMAX values are indicated with +. Outlier values are indicated by dots. (D) 89Zr-Df-IAB22M2C mean tumor uptake in patients who received 0.5 and 1.5 mg of minibody mass. BM = bone marrow; LN = lymph nodes.
- FIGURE 3.
A 77-y-old man with metastatic melanoma treated with pembrolizumab. CT and fused 18F-FDG PET/CT images (left) acquired at approximately 8 mo after initiation of immunotherapy demonstrate 2 18F-FDG–avid nodal metastases in right neck (SUVMAX = 8.0, top image; SUVMAX = 16.8, bottom image), which could represent viable metastases. Corresponding CT and fused CD8 PET/CT images (right) obtained at 1 mo after 18F-FDG PET/CT demonstrate significant tracer activity in both metastases (SUVMAX = 5.4, top image; SUVMAX = 14.6, bottom image), which suggests that some of the 18F-FDG activity could be due to tumor-infiltrating CD8+ T cells rather than tumor cells. Follow-up imaging over the next 6 mo demonstrated stable disease, supportive of this hypothesis.
- FIGURE 4.
A 71-y-old man with locally advanced stage III melanoma treated with pembrolizumab. Baseline CT and fused 18F-FDG PET/CT images (left) demonstrate 2 18F-FDG–avid metastases in left axilla (SUVMAX = 10.0, medial node; SUVMAX = 7.6, lateral node). CT and fused CD8 PET/CT images (middle) obtained at 28 d after start of immunotherapy demonstrate increased tracer activity in both metastases (SUVMAX = 9.5, medial node; SUVMAX = 10.0, lateral node), suggestive of tumor infiltration by CD8+ T cells. Follow-up imaging with contrast-enhanced CT (right) demonstrated complete response to therapy.
Tables
Characteristic All patients (n = 15) Median age (y) 64 (range, 
)Sex (n) Male 9 (60) Female 6 (40) Tumor type (n) Melanoma 8 (53) Non–small cell lung carcinoma 6 (40) Hepatocellular carcinoma 1 (7) Treatment profile at the time of imaging (n) On immunotherapy ( mo)3 (20) On immunotherapy ( mo)5 (33) On targeted therapy ( mo)2 (13) Discontinued prior treatment ( mo)2 (13) Treatment naïve 3 (20) Data in parentheses are percentages unless otherwise indicated.
Supplemental Data
Files in this Data Supplement:
In this issue
Jump to section
Related Articles
Cited By...
- Approaches to Imaging Immune Activation Using PET
- Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity
- FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma
- Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer
- Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8+ T-cell infiltration
- Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer
- Making the effect visible - OX40 targeting nanobodies for in vivo imaging of activated T cells
- Evolocumab as an immunomodulator in glioma: A window of opportunity trial evaluating PCSK9 inhibition to enhance surface MHC-I on tumor
- Impact of human CD8+ T cell senescence on 89Zr radiolabelling and homing properties
- Imaging With PET/CT of Diffuse CD8 T-Cell Infiltration of Skeletal Muscle in Patients With Inclusion Body Myositis
- Two birds with one stone: human SIRP{alpha} nanobodies for functional modulation and in vivo imaging of myeloid cells
- First-in-human immunoPET imaging of COVID-19 convalescent patients using dynamic total-body PET and a CD8-targeted minibody
- Single-Domain Antibody Theranostics on the Horizon
- MRI techniques for immunotherapy monitoring